Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.56 |
| ▸ | PLAU | P00749 | 4/20 | 0.56 |
| ▸ | F10 | P00742 | 4/20 | 0.56 |
| ▸ | PLG | P00747 | 3/20 | 0.56 |
| ▸ | PLAT | P00750 | 3/20 | 0.56 |
| ▸ | KLK8 | O60259 | 2/20 | 0.56 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.56 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | KLK2 | P20151 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7387182 | 0.99 | F2 (0.55) | F2PLAUF10PLGPLAT | |
| Hydrochloric Acid SCHEMBL7422244 | 0.99 | F2 (0.55) | F2PLAUF10PLGPLAT | |
| SCHEMBL1363820 | 0.87 | F2 (0.49) | F2PLAUF10PLGPLAT | |
| SCHEMBL17008884 | 0.87 | PARP10 (0.51) | F2PLAUF10PLGPLAT | |
| SCHEMBL131325 | 0.86 | NPSR1 (0.50) | PLAUKLK1RECQLKMT2AMEN1 | |
| SCHEMBL5147638 | 0.82 | NPSR1 (0.54) | PLAURECQLKMT2AMEN1LMNA | |
| SCHEMBL17126242 | 0.82 | NPSR1 (0.43) | F2PLAUF10PLGPLAT | |
| Bromide SCHEMBL5146297 | 0.81 | NPSR1 (0.53) | PLAURECQLKMT2AMEN1LMNA | |
| SCHEMBL6097844 | 0.80 | PLAU (0.72) | F2PLAUF10PLGPLAT | |
| SCHEMBL6842194 | 0.80 | PLAU (0.72) | F2PLAUF10PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615946-B1 | PROTEOLYTIC AND COVALENT ANTIBODIES | PAUL SUDHIR (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9006388-B2 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent | Paul, Sudhir (US) | 2015-04-14 | — | — | US | disclosed |
| US-8980646-B2 | Proteolytic and covalent antibodies | PAUL, SUDHIR (US) | 2015-03-17 | — | — | US | disclosed |
| US-8617549-B2 | Bispecific nanobodies as a therapeutic for alzheimer's disease | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120230999-A1 | BISPECIFIC NANOBODIES AS A THERAPEUTIC FOR ALZHEIMER'S DISEASE | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2012-09-13 | — | — | US | disclosed |
| US-20110287031-A1 | Covalently reactive transition state analogs and methods of use thereof | PAUL, SUDHIR, DR. | 2011-11-24 | — | — | US | disclosed |
| WO-2011031720-A1 | BISPECIFIC NANOBODIES AS A THERAPEUTIC FOR ALZHEIMER'S DISEASE | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2011-03-17 | — | — | WO | disclosed |
| EP-2091973-A2 | BINARY EPITOPE ANTIBODIES AND B CELL SUPERANTIGEN IMMUNE STIMULANTS | Paul, Sudhir (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090131328-A1 | FURIN INHIBITORS | SMITH ROBERT E | 2009-05-21 | — | — | US | disclosed |
| US-20090117115-A1 | Binary epitope antibodies and B cell superantigen immune stimulants | PAUL, SUDHIR, PH.D | 2009-05-07 | — | — | US | disclosed |
| EP-1610808-A2 | COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING | University of Texas Medical School (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050142649-A1 | Covalently reactive transition state analogs and methods of use thereof | PAUL, SUDHIR, DR. | 2005-06-30 | — | — | US | disclosed |
| US-6855804-B2 | Covalently reactive transition state analogs and methods of use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-02-15 | — | — | US | disclosed |
| WO-2004087735-A2 | PROTEOLYTIC AND COVALENT ANTIBODIES | THE UNIVERSITY OF TEXAS (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087059-A2 | COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING | THE UNIVERSITY OF TEXAS (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1373307-A2 | COVALENTLY REACTIVE TRANSITION STATE ANALOGS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030078203-A1 | Covalently reactive transition state analogs and methods of use thereof | PAUL, SUDHIR, DR. | 2003-04-24 | — | — | US | disclosed |
| WO-2002079223-A9 | COVALENTLY REACTIVE TRANSITION STATE ANALOGS AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002079223-A2 | COVALENTLY REACTIVE TRANSITION STATE ANALOGS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-1995029691-A1 | PROLINE PHOSPHONATE DERIVATIVES | GEORGIA TECH RESEARCH CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131328-A1 | FURIN INHIBITORS | FURIN, PREP, TMPRSS15 | F2 192/4885PLAU 76/4885F10 204/4885 |
| US-20050142649-A1 | Covalently reactive transition state analogs and methods of use thereof | SPR, FCGR3B, CD2 | F2 1565/4885PLAU 1537/4885F10 1799/4885 |
| US-20120230999-A1 | BISPECIFIC NANOBODIES AS A THERAPEUTIC FOR ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | F2 4339/4885PLAU 1717/4885F10 3765/4885 |
| US-20110287031-A1 | Covalently reactive transition state analogs and methods of use thereof | SPR, FCGR3B, CD2 | F2 1565/4885PLAU 1537/4885F10 1799/4885 |
| US-20030078203-A1 | Covalently reactive transition state analogs and methods of use thereof | SPR, FCGR3B, CD2 | F2 1565/4885PLAU 1537/4885F10 1799/4885 |
| US-20090117115-A1 | Binary epitope antibodies and B cell superantigen immune stimulants | CD69, CD14, CD4 | F2 4567/4885PLAU 4427/4885F10 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.